Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.32 |
| ▸ | NQO2 | P16083 | 6/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854887 | 1.00 | MTNR1A (0.32) | MTNR1AMTNR1BNQO2GAA | |
| SCHEMBL5854225 | 0.93 | ALDH1A1 (0.33) | — | |
| SCHEMBL5854319 | 0.93 | MTNR1A (0.31) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL7813218 | 0.91 | SIGMAR1 (0.32) | — | |
| SCHEMBL5856235 | 0.87 | — | — | |
| SCHEMBL6940319 | 0.87 | ESR1 (0.33) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL7087556 | 0.87 | ESR1 (0.33) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5856061 | 0.85 | ESR1 (0.40) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5854915 | 0.85 | ESR1 (0.40) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5855627 | 0.84 | MTNR1A (0.32) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610733-B2 | Antiestrogen, therapeutic agent for breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1241165-A1 | OPTICALLY ACTIVE CHROMAN AND THIOCHROMAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | NR5A1, CYP19A1, SHBG | MTNR1A 108/4885MTNR1B 302/4885NQO2 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.